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The relationship between interleukin-6 and C-reactive protein was evaluated in patients with benign (n¼59) and malignant (n¼86)
prostate disease. The correlation coefficients for patients with benign prostatic disease and prostate cancer were rs¼0.632, Po0.001
and rs¼0.663, Po0.001, respectively. These results indicate that the relationship between interleukin-6 and C-reactive protein is
similar in patients with benign and malignant prostate disease.
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The systemic inflammatory response is an obligatory response of
the body to infection, surgery or trauma. There is also increasing
evidence that the presence of a systemic inflammatory response, as
evidenced by increased circulating concentrations of C-reactive
protein, is associated with early recurrence and poor survival in a
variety of common hormone-independent tumours (Neilsen et al,
2000; Scott et al, 2002; McMillan et al, 2003). There is also some
evidence that a similar relationship exists in hormone-dependent
tumours (Lewenhaupt et al, 1990; Albuquerque et al, 1995).
A number of factors appear to mediate the increased production
of C-reactive protein. In injury, the pro-inflammatory cytokines,
interleukin-1, TNF-alpha and interleukin-6 in particular, have
been shown to stimulate the production of C-reactive protein
(Gabay and Kushner, 1999). In cancer, the factors which determine
circulating concentrations of C-reactive protein are less clear, since
studies in cell lines and animal tumour models have demonstrated
that a number of factors stimulate C-reactive protein production.
For example, it has been shown that leukaemia inhibitory factor
and ciliary neurotrophic factor are also capable of inducing an
acute-phase protein response from the liver (Baumann et al, 1993;
Henderson et al, 1994; Akiyama et al, 1997). There is also evidence
that soluble receptor subunits involved in interleukin-6 signal
transduction, the soluble interleukin-6 receptor and the soluble
gp130 receptor may be important in the regulation of interleukin-6
activity and the acute-phase protein response (Narazaki et al, 1993;
Jones and Rose-John, 2002). Therefore, if in cancer patients C-
reactive protein was stimulated by factors other than interleukin-6,
then it might be expected that the relationship between
interleukin-6 and C-reactive protein would be less strong than
that in patients with benign disease.
The aim of the present study was to examine the relationship
between interleukin-6 and C-reactive protein in patients with
benign disease (BPH) and in prostate cancer.
PATIENTS AND METHODS
Consecutive patients undergoing diagnostic transrectal ultra-
sound-guided (TRUS) biopsy of prostate were included in the
study. The indication for TRUS biopsy was either a total PSA
concentration greater than 4ngml
 1 and/or an abnormal digital
rectal examination.
Prior to biopsy, a blood sample was obtained and the serum
stored at  201C prior to analysis. No patient had a digital rectal
examination within a 2-week period prior to sampling. No patient
was receiving treatment at the time of blood sampling.
None of the patients had participated in a formal screening
programme. All patients underwent a minimum of systematic
sextant biopsy. A Gleason score was allocated for each tumour. The
Gleason score reflects tumour heterogeneity by combining primary
and secondary patterns into a composite score, which has been
shown to be an important predictor of disease recurrence and
survival (Epstein et al, 1993). Gleason scores were compressed as
recommended previously (Bostwick et al, 2000).
The study was approved by the local Research Ethics
Committee. All subjects were informed of the purpose and
procedure of the study and all gave written consent.
Total PSA was measured using the Bayer ADVIA Centaur Assay
system (Bayer PLC, Bayer House, Newbury, UK). Inter-assay
variability was o6% for total PSA.
Interleukin-6 concentrations were measured using a sensitive
solid-phase enzyme-linked immunosorbent assay (R&D Systems
Europe Ltd, Abingdon, UK). The lower level of detection was
0.2pgl
 1 and the intra-assay variability was less than 6% over the
sample concentration range.
C-reactive protein concentration was measured using a sensitive
double-antibody sandwich ELISA with rabbit anti-human
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C-reactive protein. The assay was linear from 0.1 to 5mgl
 1 and
logarithmic thereafter. Inter-assay variation was less than 10%
over the sample concentrations range.
Statistics
Data are presented as the median (range), and, where appropriate,
differences between control and cancer groups were examined
using the Mann–Whitney U test. Correlations between two
variables were calculated using Spearman’s rank correlation test.
As the distribution of interleukin-6 and C-reactive protein
concentrations was skewed, they were logarithmically transformed
to illustrate their relationship in patients with benign prostatic
disease and prostate cancer. Analysis was carried out using the
statistics package SPSS (SPSS Inc., Chicago, IL, USA).
RESULTS
A total of 145 patients (59 with benign prostatic disease and 86
with prostate cancer) were included in the study. The character-
istics of the patients with benign prostatic disease and prostate
cancer are shown in Table 1. The majority of patients with prostate
cancer had localised or locally advanced disease and had a low
Gleason score. Compared to patients with benign prostatic disease,
the cancer patients had higher circulating concentrations of total
PSA (Po0.001). There were no significant differences in circulat-
ing concentrations of interleukin-6 and C-reactive protein between
patients with benign disease and prostate cancer.
The relationship between circulating concentrations of inter-
leukin-6 and C-reactive protein in patients with benign prostatic
disease and prostate cancer is shown in Figure 1. The correlation
coefficients for patients with benign prostatic disease and prostate
cancer were rs¼0.632, Po0.001 and rs¼0.663, Po0.001, respec-
tively.
The relationship between Gleason score, PSA, interleukin-6 and
C-reactive protein in the patients with prostate cancer is shown in
Table 2. With increasing Gleason scores, there were significant
increases in total PSA (Po0.05), interleukin-6 (Po0.01) and C-
reactive protein (Po0.01). There was a significant correlation
between Gleason score and total PSA (rs¼0.364, P¼0.001),
interleukin-6 (rs¼0.311, P¼0.004) and C-reactive protein
(rs¼0.304, P¼0.004). There was no significant association
between total PSA and either interleukin-6 or C-reactive
protein.
DISCUSSION
In the present study, there were no significant differences in the
circulating concentrations of either interleukin-6 or C-reactive
protein between patients with benign prostatic disease and those
with prostate cancer. Furthermore, the relationship between
interleukin-6 and C-reactive protein was similar in both patient
groups.
In the cancer patients, there was a significant increase in both
interleukin-6 and C-reactive protein concentration with increasing
tumour grade. These results are also consistent with previous
observations that concentrations of interleukin-6 and its receptor
are increased in patients with a Gleason score greater than 7
(Shariat et al, 2001). This might suggest that the tumour was
responsible for the increased production of interleukin-6. How-
ever, the increases in interleukin-6 and C-reactive protein were
independent of total PSA.
An alternative explanation would be that the source of
interleukin-6 is the host inflammatory cells. It is therefore of
interest that recent studies have shown that a pronounced
inflammatory infiltrate in the tumour was associated with poor
outcome in patients with prostate cancer (Irani et al, 1999;
McArdle et al, 2004).
Taken together, these observations confirm that interleukin-6 is
predominantly responsible for the elaboration of C-reactive
protein. Furthermore, they suggest that interleukin-6 is produced
primarily by the host rather than the tumour. Moreover, it may
also be that interleukin-6, produced by tumour-infiltrating
leucocytes, stimulates tumour cell proliferation and promotes
leucocyte recruitment as part of an autocrine growth factor loop
(Corcoran and Costello, 2003).
In summary, the results of the present study indicate that the
relationship between interleukin-6 and C-reactive protein is
similar in patients with benign and malignant prostate disease.
Table 1 Characteristics of patients with benign prostatic disease and
prostate cancer
Benign
prostatic
disease (n¼59)
Prostate
cancer
(n¼86) P-value
Age (p70/470 years) 45/14 52/34 0.069
Stage (T1–T2/T3–T4/Met) 37/37/12
Gleason score (2–6, 7, 8–10) 46/24/16
Total PSA (ngml
 1)
a 7.0 (0.8–39) 14.6 (0.5–146) o0.001
Interleukin-6 (pgml
 1)
a 2.3 (0.7–12.9) 2.3 (0.8–28.1) 0.526
C-reactive protein (mgl
 1)
a 2.0 (0.1–21) 1.8 (0.3–50) 0.891
aMedian (range).
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Figure 1 Relationship between circulating concentrations of interleukin-
6 and C-reactive protein in patients with benign prostatic disease (J) and
prostate cancer (K).
Table 2 Relationship between inflammatory parameters and Gleason
score in patients with prostate cancer
Gleason
score 2–6
(n¼46)
Gleason
score 7
(n¼24)
Gleason
score 8–10
(n¼16) P-value
Age (p70/470 years) 31/15 12/12 9/7 0.343
Stage (T1–T2/T3–T4/
Met)
30/14/2 4/17/3 3/6/7 o0.001
Total PSA (ngml
 1)
a 11.0 (0.5–76) 19.8 (3.7–116)18.7 (4.8–146) 0.025
Interleukin-6 (pgml
 1)
a 1.9 (0.8–11.4) 3.1 (0.8–28.1) 3.0 (1.1–9.3) o0.005
C-reactive protein
(mgl
 1)
a
1.1 (0.3–18.7) 2.7 (0.3–50) 3.3 (0.8–12.5) o0.005
aMedian (range).
Systemic inflammatory response in prostate cancer
PA McArdle et al
1756
British Journal of Cancer (2004) 91(10), 1755–1757 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lREFERENCES
Akiyama Y, Kajimura N, Matsuzaki J, Kikuchi Y, Imai N, Tanigawa M,
Yamaguchi K (1997) In vivo effect of recombinant human leukemia
inhibitory factor in primates. Jpn J Cancer Res 88: 578–583
Albuquerque KV, Price MR, Badley RA, Jonrup I, Pearson D, Blamey RW,
Robertson JF (1995) Pre-treatment serum levels of tumour markers in
metastatic breast cancer: a prospective assessment of their role in
predicting response to therapy and survival. Eur J Surg Oncol 21:
504–509
Baumann H, Ziegler SF, Mosley B, Morella KK, Pajovic S, Gearing DP
(1993) Reconstitution of the response to leukemia inhibitory factor,
oncostatin M, and ciliary neurotrophic factor in hepatoma cells. J Biol
Chem 268: 8414–8417
Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford
D, Gospadarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF,
Pollack A, Srigley JR, Yarbro JW (2000) Prognostic factors in prostate
cancer. College of American Pathologists Consensus Statement 1999.
Arch Pathol Lab Med 124: 995–1000
Corcoran NM, Costello AJ (2003) Interleukin-6: minor player or starring
role in the development of hormone-refractory prostate cancer? BJU Int
91: 545–553
Epstein JI, Pizov G, Walsh PC (1993) Correlation of pathologic findings
with progression after radical retropubic prostatectomy. Cancer 71:
3582–3593
Gabay C, Kushner I (1999) Acute-phase proteins and other systemic
responses to inflammation. N Engl J Med 340: 448–454
Henderson JT, Seniuk NA, Richardson PM, Gauldie J, Roder JC (1994)
Systemic administration of ciliary neurotrophic factor induces cachexia
in rodents. J Clin Invest 93: 2632–2638
Irani J, Goujon JM, Ragni E, Peyrat L, Hubert J, Saint F, Mottet N (1999)
High-grade inflammation in prostate cancer as a prognostic factor for
biochemical recurrence after radical prostatectomy. Pathologist Multi
Center Study Group. Urology 54: 467–472
Jones SA, Rose-John S (2002) The role of soluble receptors in cytokine
biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim
Biophys Acta 1592: 251–263
Lewenhaupt A, Ekman P, Eneroth P, Nilsson B (1990) Tumour markers as
prognostic aids in prostatic carcinoma. Br J Urol 66: 182–187
McArdle PA, Canna K, McMillan DC, McNicol A-M, Campbell R,
Underwood MA (2004) The relationship between T-lymphocyte subset
infiltration and survival in patients with prostate cancer. Br J Cancer 91:
541–543
McMillan DC, Canna K, McArdle CS (2003) Systemic inflammatory
response predicts survival following curative resection of colorectal
cancer. Br J Surg 90: 215–219
Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y,
Yancopoulos GD, Taga T, Kishimoto T (1993) Soluble forms of the
interleukin-6 signal-transducing receptor component gp130 in human
serum possessing a potential to inhibit signals through membrane-
anchored gp130. Blood 82: 1120–1126
Neilsen HJ, Christensen IJ, Sorensen S, Moesgaard F, Brunner N (2000)
Preoperative plasma plasminogen activator inhibitor type-1 and serum
C-reactive protein levels in patients with colorectal cancer. The RANXO5
Colorectal Cancer Study Group. Ann Surg Oncol 7: 617–623
Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R
(2002) The systemic inflammatory response, weight loss, performance
status and survival in patients with inoperable non-small cell lung
cancer. Br J Cancer 87: 264–267
Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM (2001)
Plasma levels of interleukin-6 and its soluble receptor are associated with
prostate cancer progression and metastasis. Urology 58: 1008–1015
Systemic inflammatory response in prostate cancer
PA McArdle et al
1757
British Journal of Cancer (2004) 91(10), 1755–1757 & 2004 Cancer Research UK
C
l
i
n
i
c
a
l